These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 24365381)

  • 1. Galectin-3 testing: validity of a novel automated assay in heart failure patients with reduced ejection fraction.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Chim Acta; 2014 Feb; 429():189-93. PubMed ID: 24365381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of Galectin-3 with the ARCHITECT assay: Clinical validity and cost-effectiveness in patients with heart failure.
    Gruson D; Mancini M; Ahn SA; Rousseau MF
    Clin Biochem; 2014 Aug; 47(12):1006-9. PubMed ID: 24925289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial.
    Lopez-Andrès N; Rossignol P; Iraqi W; Fay R; Nuée J; Ghio S; Cleland JG; Zannad F; Lacolley P
    Eur J Heart Fail; 2012 Jan; 14(1):74-81. PubMed ID: 22089058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
    Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
    J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of sST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy.
    Gawor M; Śpiewak M; Janas J; Kożuch K; Wróbel A; Mazurkiewicz Ł; Baranowski R; Marczak M; Grzybowski J
    Kardiol Pol; 2017; 75(10):997-1004. PubMed ID: 28612913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure.
    Lok DJ; Lok SI; Bruggink-André de la Porte PW; Badings E; Lipsic E; van Wijngaarden J; de Boer RA; van Veldhuisen DJ; van der Meer P
    Clin Res Cardiol; 2013 Feb; 102(2):103-10. PubMed ID: 22886030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure.
    Gopal DM; Kommineni M; Ayalon N; Koelbl C; Ayalon R; Biolo A; Dember LM; Downing J; Siwik DA; Liang CS; Colucci WS
    J Am Heart Assoc; 2012 Oct; 1(5):e000760. PubMed ID: 23316284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional value of Galectin-3 to BNP in acute heart failure patients with preserved ejection fraction.
    Beltrami M; Ruocco G; Dastidar AG; Franci B; Lucani B; Aloia E; Nuti R; Palazzuoli A
    Clin Chim Acta; 2016 Jun; 457():99-105. PubMed ID: 27067445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the plasma brain natriuretic peptide in differentiating patients with congestive heart failure from other diseases.
    Sirithunyanont C; Leowattana W; Sukumalchantra Y; Chaisupamonkollarp S; Watanawaroon S; Chivatanaporn B; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2003 May; 86 Suppl 1():S87-95. PubMed ID: 12866774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of proBNP1-108 testing for the risk stratification of patients with systolic heart failure.
    Gruson D; Lepoutre T; Ahn SA; Rousseau MF
    Peptides; 2013 Dec; 50():125-8. PubMed ID: 24140405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic profile provides prognostic value better than galectin-3 in patients with heart failure.
    Wang CH; Cheng ML; Liu MH; Kuo LT; Shiao MS
    J Cardiol; 2017 Jul; 70(1):92-98. PubMed ID: 28318874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-center determination of galectin-3 assay performance characteristics: Anatomy of a novel assay for use in heart failure.
    Christenson RH; Duh SH; Wu AH; Smith A; Abel G; deFilippi CR; Wang S; Adourian A; Adiletto C; Gardiner P
    Clin Biochem; 2010 May; 43(7-8):683-90. PubMed ID: 20153309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative value of BNP and NT-proBNP in diagnosis of heart failure.
    Fonseca C; Sarmento PM; Minez A; Gonçalves E; Covas R; Dias AR; Pina MJ; Ceia F
    Rev Port Cardiol; 2004; 23(7-8):979-91. PubMed ID: 15478324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive origin.
    López B; González A; Querejeta R; Zubillaga E; Larman M; Díez J
    Eur J Heart Fail; 2015 Apr; 17(4):385-92. PubMed ID: 25684565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes of serum N-terminal pro-brain natriuretic peptide levels in patients with cardiovascular diseases and its clinical significance].
    Yang CL; Qiu YR; Zhou F; Feng PF
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):866-9. PubMed ID: 18504223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prognostic value of plasma galectin-3 in chronic heart failure patients is maintained when treated with mineralocorticoid receptor antagonists.
    Koukoui F; Desmoulin F; Galinier M; Barutaut M; Caubère C; Evaristi MF; Murat G; De Boer R; Berry M; Smih F; Rouet P
    PLoS One; 2015; 10(3):e0119160. PubMed ID: 25786035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.